CD8A and prostate adenocarcinoma: In most cancers, including adrenocortical carcinoma (ACC), CESC, COAD, DLBC, KIRC, LIHC, LUAD, prostate adenocarcinoma, SKCM and UCEC (the cancer types shown in the green box), the expression levels of lenvatinib target genes generally showed a negative correlation with the levels of CD8+ T cell infiltrates (≥8 blue squares and more than four of them have an r ≤ –0.15).